AptarGroup (ATR) Bank of America 2026 Global Agriculture and Materials Conference summary

Key business highlights

• Proprietary drug delivery systems, especially nasal, are a core strength and expanding into new therapeutic areas beyond allergies, including GLP-1, neurodegenerative, and cardiovascular diseases.

• Recognized as a global leader in drug and consumer product dosing, dispensing, and protection technologies, with a diversified portfolio spanning pharma, beauty, closures, and food markets.

• Consumer-facing businesses have improved, with closures back in their target range and beauty resuming growth, benefiting from sustainability leadership.

• Global supply chain is structured regionally, enabling resilience amid geopolitical tensions and supporting growth in all major markets.

• China operations are robust, leveraging local talent and infrastructure for faster product development and strong profitability.

Financial and operational outlook

• Guidance for Q1 remains at $1.13 to $1.21 EPS, with trends stable and no major changes since Q4; emergency medicine (naloxone) is the main exception.

• Achieved total reported sales of $3.78B in 2025, with 5% overall growth; pharma led with $1.74B (6% growth), beauty at $1.31B (7% growth), and closures at $730M (2% growth).

• Pharma margins are expected to be strong, with most negative impact from emergency medicine destocking occurring in the first half of the year.

• Consumer healthcare and injectables are growing briskly, with active materials also performing well; overall, the company expects to remain within its long-term margin range.

• Strong balance sheet and disciplined capital allocation, with a long-term leverage target of 1-3x and significant returns to shareholders through dividends and buybacks.

Pharma pipeline and innovation

• Maintains a robust innovation pipeline with over 7,000 active and pending patents, and invests approximately 3% of sales in R&D, primarily focused on pharma.

• Pharma pipeline is robust and diversified, with growth in indications such as GLP-1, neurodegenerative, mental health, and cardiovascular diseases.

• Recent launches include alternatives to injection for edema and tachycardia, expanding the use of nasal delivery devices.

• Inhalation products are transitioning to low global warming potential propellants, creating new opportunities.

• Unidose and Bidose devices are key drivers in pharma, valued for precise dosing and reliability, but not the sole growth contributors.